ANI Pharmaceuticals, Inc.
210 Main Street West
Baudette
MN
United States
282 articles about ANI Pharmaceuticals, Inc.
-
ANI Pharmaceuticals Strengthens Rare Disease Business Unit Leadership Team
2/24/2022
ANI Pharmaceuticals appoints Mary Pao, M.D., Ph.D., as Chief Medical Officer, Rare Disease, and Elizabeth Powell, J.D., as Chief Compliance Officer and Head of Legal, Rare Disease.
-
ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders
1/24/2022
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced the U.S. commercial availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) 80 U/mL.
-
ANI Pharmaceuticals to Present at the H.C. Wainwright Bioconnect Virtual Conference
1/3/2022
ANI Pharmaceuticals, Inc. announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows.
-
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP
12/21/2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the Abbreviated New Drug Application for Rifabutin Capsules USP, 150 mg.
-
Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)
12/20/2021
Eton Pharmaceuticals, Inc and ANI Pharmaceuticals, Inc (Nasdaq: ANIP), a bio-pharmaceutical company serving patients in need through the development and manufacturing of high-quality generic and branded medicines, today announced the commercial launch of Carglumic Acid tablets.
-
ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses
11/22/2021
Combined company creates generics growth engine with technical capabilities to bring complex, high-value products to market in efficient and cost effect manner.
-
ANI Pharmaceuticals to Present at the Piper Sandler 33rd Annual Healthcare Conference 2021
11/22/2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present virtually at the Piper Sandler 33rd Annual Healthcare Conference.
-
ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma
11/11/2021
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Federal Trade Commission (the FTC) has accepted the proposed consent order in connection with ANI's definitive agreement to acquire Novitium Pharma.
-
ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock
11/8/2021
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (ANI or the Company) today announced the closing of its previously announced underwritten public offering.
-
ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock
11/4/2021
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI” or the "Company") today announced the pricing of an underwritten public offering of 1,500,000 shares of its common stock at a public offering price of $50.00 per share.
-
ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock - Nov 03, 2021
11/3/2021
ANI Pharmaceuticals, Inc. announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
-
ANI Pharmaceuticals Reports Third Quarter 2021 Results
11/1/2021
ANI Pharmaceuticals, Inc. announced business highlights and financial results for the three months ended September 30, 2021.
-
ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin™ Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome
11/1/2021
ANI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the Company’s supplemental New Drug Application for Purified Cortrophin™ Gel for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis and rheumatoid arthritis, in addition to excess urinary protein due to nephrotic syndrome.
-
ANI Pharmaceuticals to Discuss Third Quarter 2021 Financial Results on November 1, 2021
10/29/2021
ANI Pharmaceuticals, Inc. announced that the Company will release its third quarter 2021 financial results on Monday, November 1, 2021.
-
ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021
9/20/2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021.
-
ANI Pharmaceuticals Announces Launch of Nebivolol Tablets
9/17/2021
ANI Pharmaceuticals, Inc. announced the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.
-
ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome
8/31/2021
ANI Pharmaceuticals, Inc. announced that the Company’s supplemental New Drug Application for Purified Cortrophin® Gel has been accepted by the U.S. Food and Drug Administration for review.
-
ANI Pharmaceuticals Reports Second Quarter 2021 Results
8/6/2021
ANI Pharmaceuticals, Inc., (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2021.
-
ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021
7/22/2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2021 financial results on Friday, August 6, 2021.
-
ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA
7/6/2021
ANI Pharmaceuticals, Inc. announced that the Company has re-filed its supplemental new drug application for Cortrophin® Gel with the U.S. Food and Drug Administration.